Vertex Pharmaceuticals (Germany) Performance
| VX1 Stock | EUR 444.80 0.80 0.18% |
Vertex Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The entity has a beta of 0.94, which indicates possible diversification benefits within a given portfolio. Vertex Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Vertex Pharmaceuticals is expected to follow. Vertex Pharmaceuticals right now has a risk of 1.82%. Please validate Vertex Pharmaceuticals treynor ratio, value at risk, downside variance, as well as the relationship between the maximum drawdown and potential upside , to decide if Vertex Pharmaceuticals will be following its existing price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Vertex Pharmaceuticals Incorporated are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable basic indicators, Vertex Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 6.8 B |
Vertex |
Vertex Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 42,775 in Vertex Pharmaceuticals Incorporated on September 19, 2024 and sell it today you would earn a total of 1,295 from holding Vertex Pharmaceuticals Incorporated or generate 3.03% return on investment over 90 days. Vertex Pharmaceuticals Incorporated is currently producing 0.0626% returns and takes up 1.8178% volatility of returns over 90 trading days. Put another way, 16% of traded stocks are less volatile than Vertex, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Vertex Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vertex Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vertex Pharmaceuticals Incorporated, and traders can use it to determine the average amount a Vertex Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0344
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | VX1 | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.82 actual daily | 16 84% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Vertex Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vertex Pharmaceuticals by adding it to a well-diversified portfolio.
Vertex Pharmaceuticals Fundamentals Growth
Vertex Stock prices reflect investors' perceptions of the future prospects and financial health of Vertex Pharmaceuticals, and Vertex Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vertex Stock performance.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.37 % | |||
| Operating Margin | 0.49 % | |||
| Current Valuation | 67.44 B | |||
| Shares Outstanding | 257.09 M | |||
| Price To Earning | 18.50 X | |||
| Price To Book | 6.23 X | |||
| Price To Sales | 8.51 X | |||
| Revenue | 8.93 B | |||
| EBITDA | 4.44 B | |||
| Cash And Equivalents | 3.95 B | |||
| Cash Per Share | 15.37 X | |||
| Total Debt | 656.95 M | |||
| Debt To Equity | 12.90 % | |||
| Book Value Per Share | 54.13 X | |||
| Cash Flow From Operations | 4.13 B | |||
| Earnings Per Share | 11.89 X | |||
| Total Asset | 18.15 B | |||
About Vertex Pharmaceuticals Performance
By analyzing Vertex Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Vertex Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Vertex Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vertex Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2500 people.Things to note about Vertex Pharmaceuticals performance evaluation
Checking the ongoing alerts about Vertex Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vertex Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 96.0% of the company outstanding shares are owned by institutional investors |
- Analyzing Vertex Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vertex Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Vertex Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vertex Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vertex Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vertex Pharmaceuticals' stock. These opinions can provide insight into Vertex Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |